-
Dec 15, 2025, 09:10 AM
by
Flare V11 features AI generative chemistry technology, enabling researchers to generate new, diverse, drug-like molecules, while new AI Assistants unlock efficiency gains in the user experience and automate the creation of custom workflows.
Full story
-
Dec 15, 2025, 09:10 AM
by
CluePoints, provider of leading statistical and AI-driven software solutions, has won the ‘Best Contract Research Organization– Specialist Providers’ category at the 2025 Scrip Awards.
Full story
-
Dec 15, 2025, 09:10 AM
by
Built directly into the elluminate ecosystem, the agents combine governed data with explainable intelligence to accelerate decisions
Full story
-
Dec 12, 2025, 01:01 AM
by
User Not Found
Bio-IT World | Researchers from the University of Illinois Urbana-Champaign used deep learning and large-scale computer simulations to identify structural differences in synthetic cannabinoid molecules that cause them to bind to human brain receptors differently from classical cannabinoids.
Full story
-
Dec 11, 2025, 10:09 AM
by
4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced a collaboration with AMD and Oracle to advance predictive oncology and accelerate clinical trials. Using AMD EPYC™ CPUs on Oracle Cloud Infrastructure (OCI), 4D Path’s QPOR™ platform—a physics-informed, AI-driven, deterministic software engine—can convert routine biopsy images into interpretable biomarkers of tumor and immune response faster and at lower cost.
Full story
-
Dec 11, 2025, 09:22 AM
by
User Not Found
Bio-IT World | Historically, cancer treatment has relied on a one-size-fits-all approach known as the Standard of Care, where patients are treated based on population averages. But cancer is not a single disease; it’s thousands of distinct conditions, each driven by unique biology.
Full story
-
Dec 10, 2025, 09:25 AM
by
Ansa Biotechnologies announced the appointment of Geoff Hamilton as Chief Financial Officer and Chief Business Officer.
Full story
-
Dec 10, 2025, 09:25 AM
by
New integrations with industry leaders in EDC, eConsent, IRT/RTSM, eCOA, payments, and patient engagement expands Advarra's connected ecosystem, giving sponsors, CROs, and research sites secure, centralized access to critical study technologies
Full story
-
Dec 10, 2025, 09:25 AM
by
New York Gastroenterology Associates, LLP , New York City’s leading independent gastroenterology practice, is working with Proscia®, a pathology AI company, to advance its standard of excellence.
Full story
-
Dec 10, 2025, 09:25 AM
by
Bio-IT World Conference & Expo, the premier global event uniting more than 2,900 biopharma, biomedical research, healthcare, informatics and technology leaders, returns to Boston May 19-21, 2026 to celebrate its 25th annual program with a direct impact on the future of precision medicine.
Full story
-
Dec 8, 2025, 10:02 AM
by
User Not Found
Bio-IT World | Oxford Nanopore Technologies named a new CEO this morning, choosing an executive with extensive diagnostics experience. Francis Van Parys, currently CEO of Radiometer, will join Oxford Nanopore and the Board as an Executive Director on March 2, 2026.
Full story
-
Dec 8, 2025, 08:10 AM
by
Landmark study from Inocras, Samsung Medical Center and Seoul St. Mary’s Hospital Researchers explores the whole genomes of 1,364 breast cancers, uncovering predictive biomarkers that link genomic signatures to potential treatment outcomes and support advancing precision oncology.
Full story
-
Dec 8, 2025, 08:10 AM
by
Silverstone, UK, 8 December 2025: Lab Thread Ltd, a UK‐based life science software company, today announced the beta launch of its flagship unified lab software platform. Lab Thread is uniquely designed to provide an intuitive and adoptable platform with powerful collaborative features – helping to unite researchers, lab operations and scientific data from across diverse teams and advance scientific discovery.
Full story
-
Dec 5, 2025, 09:12 AM
by
Full story
-
Dec 5, 2025, 09:12 AM
by
Company’s third Human Factors Formative Study shows that 95% of participants prefer the Vaxess microarray patch to traditional injection devices
Full story
-
Dec 4, 2025, 08:38 AM
by
PrecisionLife has announced new findings from the most detailed genetic analysis of myalgic encephalomyelitis ever conducted offering potential for faster and lower-risk routes to developing targeted treatments.
Full story
-
Dec 4, 2025, 08:38 AM
by
4D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced that the company’s Q-Plasia OncoReader (QPOR™) platform has successfully predicted treatment response in patients with early-stage triple-negative breast cancer (TNBC) using digitized baseline biopsy images. Analysis conducted within the Translational Breast Cancer Research Consortium (TBCRC) 030 clinical trial represents the first demonstration of a statistical physics and tumor biology-based computational biomarker predicting post-treatment outcomes from pre-treatment tissue alone, without any clinical or molecular inputs.
Full story
-
Dec 4, 2025, 01:01 AM
by
User Not Found
Bio-IT World | Since artificial intelligence (AI) made its way into the medical field, foundation models—machine learning systems that are trained on broad data and adaptable to a wide range of downstream tasks—have become a focus. These foundation models are used to perform various medical tasks with minimal amounts of data. Of course, this means that these models require robust training, which poses a challenge for researchers.
Full story
-
Dec 3, 2025, 09:21 AM
by
Compliance with independent security standards comes as Proscia accelerates digital pathology deployments at scale
Full story
-
Dec 3, 2025, 01:01 AM
by
User Not Found
Bio-IT World | As genetic testing becomes a routine part of modern medicine, researchers are grappling with an unintended consequence: a flood of never-before-seen genetic variants whose clinical significance is unknown. These variants of uncertain significance (VUS), now number in the tens of thousands, outpace the capacity of traditional scientific methods to determine whether they contribute to disease.
Full story